RU2012140704A - Способ профилактики и/или лечения фиброза и/или помутнения роговицы (варианты), способ получения фармацевтической композиции для профилактики и/или лечения фиброза и/или помутнения роговицы и глазная фармацевтическая композиция - Google Patents
Способ профилактики и/или лечения фиброза и/или помутнения роговицы (варианты), способ получения фармацевтической композиции для профилактики и/или лечения фиброза и/или помутнения роговицы и глазная фармацевтическая композиция Download PDFInfo
- Publication number
- RU2012140704A RU2012140704A RU2012140704/15A RU2012140704A RU2012140704A RU 2012140704 A RU2012140704 A RU 2012140704A RU 2012140704/15 A RU2012140704/15 A RU 2012140704/15A RU 2012140704 A RU2012140704 A RU 2012140704A RU 2012140704 A RU2012140704 A RU 2012140704A
- Authority
- RU
- Russia
- Prior art keywords
- treatment
- prevention
- fibrosis
- corneal
- pharmaceutical composition
- Prior art date
Links
- 206010016654 Fibrosis Diseases 0.000 title claims abstract 8
- 230000004761 fibrosis Effects 0.000 title claims abstract 8
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract 7
- 230000002265 prevention Effects 0.000 title claims abstract 7
- 238000004519 manufacturing process Methods 0.000 title claims abstract 3
- 238000000034 method Methods 0.000 title claims abstract 3
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 claims abstract 8
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 claims abstract 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 8
- 208000006069 Corneal Opacity Diseases 0.000 claims abstract 6
- 231100000269 corneal opacity Toxicity 0.000 claims abstract 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract 2
- 239000003937 drug carrier Substances 0.000 claims abstract 2
- 229920002674 hyaluronan Polymers 0.000 claims abstract 2
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract 2
- 230000002401 inhibitory effect Effects 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/709,895 | 2010-02-22 | ||
| US12/709,895 US8158589B2 (en) | 2003-08-22 | 2010-02-22 | Peptides with the capacity to bind to transforming growth factor β1 (TGF-β1) |
| PCT/EP2011/052543 WO2011101478A1 (en) | 2010-02-22 | 2011-02-21 | USE OF TRANSFORMING GROWTH FACTOR - BETA 1 (TGF-β1) INHIBITOR PEPTIDES FOR THE TREATMENT OF CORNEAL FIBROSIS AND/OR HAZE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012140704A true RU2012140704A (ru) | 2014-03-27 |
Family
ID=43757920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012140704/15A RU2012140704A (ru) | 2010-02-22 | 2011-02-21 | Способ профилактики и/или лечения фиброза и/или помутнения роговицы (варианты), способ получения фармацевтической композиции для профилактики и/или лечения фиброза и/или помутнения роговицы и глазная фармацевтическая композиция |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8158589B2 (https=) |
| EP (1) | EP2538962A1 (https=) |
| JP (1) | JP2013520405A (https=) |
| CN (1) | CN102791283A (https=) |
| AU (1) | AU2011217181A1 (https=) |
| BR (1) | BR112012020953A2 (https=) |
| CA (1) | CA2790625A1 (https=) |
| MX (1) | MX2012009748A (https=) |
| RU (1) | RU2012140704A (https=) |
| WO (1) | WO2011101478A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130158103A1 (en) * | 2011-11-23 | 2013-06-20 | The Curators Of The University Of Missouri | Method of Tissue-Selective Targeted Gene Transfer |
| ES2423382B1 (es) * | 2012-02-16 | 2014-07-15 | Consejo Superior De Investigaciones Científicas (Csic) | Inhibidor de la produccion de endoglina soluble y su aplicacion en patologias donde la endoglina soluble tiene un efecto patogenico |
| WO2013148155A1 (en) * | 2012-03-26 | 2013-10-03 | Digna Biotech Usa, Llc | Compositions and methods for the treatment of dry eye disease |
| WO2014028862A1 (en) | 2012-08-17 | 2014-02-20 | Cornell University | Use of dna in circulating exosomes as a diagnostic marker for metastasic disease |
| RU2016106641A (ru) * | 2013-07-30 | 2017-09-01 | Киото Прифекчурал Паблик Юниверсити Корпорэйшн | Терапевтические средства, направленные на ecm эндотелия роговицы |
| CA2927898C (en) * | 2013-10-31 | 2021-11-16 | Kyoto Prefectural Public University Corporation | Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium |
| WO2015072580A1 (ja) | 2013-11-14 | 2015-05-21 | 学校法人同志社 | 細胞増殖促進または細胞障害抑制による角膜内皮治療薬 |
| EP3125907A4 (en) | 2014-04-01 | 2017-11-29 | Cornell University | Use of double-stranded dna in exosomes: a novel biomarker in cancer detection |
| US11397182B2 (en) | 2014-10-07 | 2022-07-26 | Cornell University | Methods for prognosing and preventing metastatic liver disease |
| US11971402B2 (en) | 2015-04-24 | 2024-04-30 | Cornell University | Methods and reagents for determination and treatment of organotropic metastasis |
| ES2965877T3 (es) * | 2015-10-27 | 2024-04-17 | Univ Taipei Medical | Derivados de indolina para el tratamiento y/o la prevención de enfermedades fibróticas |
| JPWO2017110093A1 (ja) | 2015-12-24 | 2018-10-11 | 学校法人同志社 | ＴＧＦ−βシグナルに起因する障害を治療または予防するための医薬およびその応用 |
| MX2018014256A (es) * | 2016-05-20 | 2019-08-16 | Harvard College | Metodos de terapia genica para enfermedades y condiciones relacionadas con la edad. |
| WO2019022152A1 (ja) | 2017-07-26 | 2019-01-31 | 学校法人同志社 | ＴＧＦ－βシグナルに起因する障害を治療または予防するための医薬およびその応用 |
| WO2019234221A1 (en) | 2018-06-08 | 2019-12-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia |
| GB201908012D0 (en) * | 2019-06-05 | 2019-07-17 | Io Biotech Aps | TGF-Beta vaccine |
| RU2700941C1 (ru) * | 2019-07-05 | 2019-09-24 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр реабилитации и курортологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ РК" Минздрава России) | Способ предупреждения развития помутнения роговицы при ее механических травмах |
| RU2701178C1 (ru) * | 2019-07-10 | 2019-09-25 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр реабилитации и курортологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ РК" Минздрава России) | Способ ускорения заживления роговицы при ее механических травмах |
| CN110483648A (zh) * | 2019-08-27 | 2019-11-22 | 南京安吉生物科技有限公司 | 一种融合多肽及其应用 |
| CN110862434B (zh) * | 2019-10-28 | 2021-07-06 | 中山大学 | 一种可促进TGF-β1蛋白靶向降解的化合物及其制备方法与应用 |
| JP2020073483A (ja) * | 2019-10-30 | 2020-05-14 | 京都府公立大学法人 | 角膜内皮ｅｃｍ治療薬 |
| EP4269429A4 (en) * | 2020-12-23 | 2025-07-30 | Korea Inst Sci & Tech | NEW PEPTIDE CAPABLE OF INHIBITING TGF-BETA SIGNALING AND ITS UTILIZATION |
| CN115040535B (zh) * | 2022-08-15 | 2022-12-16 | 华南理工大学 | 硫酸化透明质酸在制备预防角膜纤维化、角膜瘢痕滴眼液中的应用 |
| WO2026027520A1 (en) | 2024-07-30 | 2026-02-05 | Disit Biotech, S.L. | Method of preparing parenteral formulations and formulations prepared therefrom |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4550022A (en) | 1981-10-05 | 1985-10-29 | Alcon Laboratories, Inc. | Tissue irrigating solution |
| JPH08151396A (ja) | 1994-11-28 | 1996-06-11 | Teijin Ltd | Ｈｌａ結合性オリゴペプチド及びそれを含有する免疫調節剤 |
| AU5593398A (en) * | 1996-12-05 | 1998-06-29 | Alcon Laboratories, Inc. | The use of inhibitors of tgf-beta's functions to ameliorate ocular pathology |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| ES2146552B1 (es) | 1998-11-24 | 2001-04-16 | Inst Cientifico Tecnol Navarra | Peptidos inhibidores de tgf/31 |
| WO2000037072A1 (en) | 1998-12-22 | 2000-06-29 | Alcon Laboratories, Inc. | Use of inhibitors of gag synthesis for the treatment of corneal haze |
| AU1533402A (en) | 2000-10-13 | 2002-04-22 | Univ Johns Hopkins | Plasminogen activator to prevent corneal and subepithelial haze after laser vision correction surgery |
| ES2304069B1 (es) * | 2003-08-22 | 2009-08-12 | Proyecto De Biomedicina Cima, S.L. | Peptidos con capacidad de unirse al factor transformante de crecimiento beta 1 (tgf-b1). |
| EP1974740A4 (en) * | 2005-10-24 | 2010-09-01 | Proyecto Biomedicina Cima Sl | USE OF TGF-BETA1 INHIBITORY PEPTIDES IN THE PREPARATION OF AN IMMUNE RESPONSE MODULATING AGENT |
| US7582609B2 (en) * | 2006-03-01 | 2009-09-01 | Digna Biotech, S.L. | Method for the treatment of skin fibrosis and suitable compositions for such treatment |
-
2010
- 2010-02-22 US US12/709,895 patent/US8158589B2/en not_active Expired - Fee Related
-
2011
- 2011-02-21 MX MX2012009748A patent/MX2012009748A/es not_active Application Discontinuation
- 2011-02-21 JP JP2012553344A patent/JP2013520405A/ja not_active Withdrawn
- 2011-02-21 BR BR112012020953A patent/BR112012020953A2/pt not_active IP Right Cessation
- 2011-02-21 CN CN2011800104876A patent/CN102791283A/zh active Pending
- 2011-02-21 CA CA2790625A patent/CA2790625A1/en not_active Abandoned
- 2011-02-21 RU RU2012140704/15A patent/RU2012140704A/ru not_active Application Discontinuation
- 2011-02-21 EP EP11704455A patent/EP2538962A1/en not_active Withdrawn
- 2011-02-21 US US13/580,103 patent/US20120315256A1/en not_active Abandoned
- 2011-02-21 AU AU2011217181A patent/AU2011217181A1/en not_active Abandoned
- 2011-02-21 WO PCT/EP2011/052543 patent/WO2011101478A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011217181A1 (en) | 2012-09-06 |
| CA2790625A1 (en) | 2011-08-25 |
| US20120315256A1 (en) | 2012-12-13 |
| CN102791283A (zh) | 2012-11-21 |
| US20100222280A1 (en) | 2010-09-02 |
| JP2013520405A (ja) | 2013-06-06 |
| EP2538962A1 (en) | 2013-01-02 |
| US8158589B2 (en) | 2012-04-17 |
| BR112012020953A2 (pt) | 2017-02-07 |
| WO2011101478A1 (en) | 2011-08-25 |
| MX2012009748A (es) | 2012-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012140704A (ru) | Способ профилактики и/или лечения фиброза и/или помутнения роговицы (варианты), способ получения фармацевтической композиции для профилактики и/или лечения фиброза и/или помутнения роговицы и глазная фармацевтическая композиция | |
| JP2013520405A5 (https=) | ||
| MX359516B (es) | Composiciones y metodos para prevenir o tratar enfermedades, afecciones, o procesos caracterizados por la proliferacion abrellante de fibro blasto y deposicion de matriz extracelular. | |
| NZ608502A (en) | Polypeptides that bind to human complement component c5 | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| MX2025005489A (es) | Uso de lumateperona para el tratamiento del trastorno bipolar ii | |
| HK1204988A1 (en) | Methods and compositions for preventing or treating ophthalmic conditions | |
| EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
| RU2013156378A (ru) | 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1н-бензимидазол-2-ил]-1н-хинолин-2-он для применения при лечении аденокистозной карциномы | |
| EA201490377A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата | |
| JP2015517488A5 (https=) | ||
| EA201590836A1 (ru) | Составы с низкой дозой панкрелипазы и кишечнорастворимым покрытием | |
| UA115139C2 (uk) | Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту | |
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| EA201490378A1 (ru) | ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β | |
| MX2017006372A (es) | Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matrix extracelular. | |
| RU2016137289A (ru) | Схема применения соединения fgf-18 | |
| RU2012108179A (ru) | Новый пептид и его применение | |
| TW201129361A (en) | Methods for treating pain | |
| MX2015007402A (es) | Fusion de hormona de crecimiento humano y albumina, formulacion y usos de los mismos. | |
| RU2013108390A (ru) | Фармацевтическая композиция для предотвращения периоперационной артериальной гипотензии у человека | |
| WO2016033432A9 (en) | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition | |
| RU2011133224A (ru) | Новые фармацевтические композиции | |
| MX336278B (es) | Composiciones y metodos para la prevencion y el tratamiento de heridas. | |
| DE602007014193D1 (de) | Behandlung psychiatrischer patienten mit schlafstörungen und/oder übermässiger tagesschläfrigkeit mit paliperidon |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20150715 |